Identification of novel compound heterozygous mutations in ACO2 in a patient with progressive cerebral and cerebellar atrophy.
ACO2
TCA cycle
aconitase
ataxia
brain atrophy
hypotonia
mitochondria
Journal
Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
26
09
2018
revised:
29
01
2019
accepted:
08
04
2019
pubmed:
21
5
2019
medline:
19
6
2020
entrez:
21
5
2019
Statut:
ppublish
Résumé
The tricarboxylic acid (TCA) cycle is a sequence of catabolic reactions within the mitochondrial matrix, and is a central pathway for cellular energy metabolism. Genetic defects affecting the TCA cycle are known to cause severe multisystem disorders. We performed whole exome sequencing of genomic DNA of a patient with progressive cerebellar and cerebral atrophy, hypotonia, ataxia, seizure disorder, developmental delay, ophthalmological abnormalities and hearing loss. We also performed biochemical studies using patient fibroblasts. We identified new compound heterozygous mutations (c.1534G > A, p.Asp512Asn and c.1997G > C, p.Gly666Ala) in ACO2, which encodes aconitase 2, a component of the TCA cycle. In patient fibroblasts, the aconitase activity was reduced to 15% of that of the control, and the aconitase 2 level decreased to 36% of that of the control. As such a decrease in aconitase 2 in patient fibroblasts was partially restored by proteasome inhibition, mutant aconitase 2 was suggested to be relatively unstable and rapidly degraded after being synthesized. In addition, the activity of the father-derived variant of aconitase 2 (p.Gly666Ala), which had a mutation near the active center, was 55% of that of wild-type. The marked reduction of aconitase activity in patient fibroblasts was due to the combination of decreased aconitase 2 amount and activity due to mutations. Reduced aconitase activity directly suppresses the TCA cycle, resulting in mitochondrial dysfunction, which may lead to symptoms similar to those observed in mitochondrial diseases.
Sections du résumé
BACKGROUND
The tricarboxylic acid (TCA) cycle is a sequence of catabolic reactions within the mitochondrial matrix, and is a central pathway for cellular energy metabolism. Genetic defects affecting the TCA cycle are known to cause severe multisystem disorders.
METHODS
We performed whole exome sequencing of genomic DNA of a patient with progressive cerebellar and cerebral atrophy, hypotonia, ataxia, seizure disorder, developmental delay, ophthalmological abnormalities and hearing loss. We also performed biochemical studies using patient fibroblasts.
RESULTS
We identified new compound heterozygous mutations (c.1534G > A, p.Asp512Asn and c.1997G > C, p.Gly666Ala) in ACO2, which encodes aconitase 2, a component of the TCA cycle. In patient fibroblasts, the aconitase activity was reduced to 15% of that of the control, and the aconitase 2 level decreased to 36% of that of the control. As such a decrease in aconitase 2 in patient fibroblasts was partially restored by proteasome inhibition, mutant aconitase 2 was suggested to be relatively unstable and rapidly degraded after being synthesized. In addition, the activity of the father-derived variant of aconitase 2 (p.Gly666Ala), which had a mutation near the active center, was 55% of that of wild-type.
CONCLUSION
The marked reduction of aconitase activity in patient fibroblasts was due to the combination of decreased aconitase 2 amount and activity due to mutations. Reduced aconitase activity directly suppresses the TCA cycle, resulting in mitochondrial dysfunction, which may lead to symptoms similar to those observed in mitochondrial diseases.
Identifiants
pubmed: 31106992
doi: 10.1002/mgg3.698
pmc: PMC6625133
doi:
Substances chimiques
ACO2 protein, human
EC 4.2.1.3
Aconitate Hydratase
EC 4.2.1.3
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00698Informations de copyright
© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
Références
Biochemistry. 1992 Mar 17;31(10):2735-48
pubmed: 1547214
J Med Genet. 2014 Dec;51(12):834-8
pubmed: 25351951
J Child Neurol. 2017 Aug;32(9):840-845
pubmed: 28545339
Proteins. 1989;5(4):289-312
pubmed: 2798408
Ann Hum Genet. 1975 Oct;39(2):193-202
pubmed: 1052766
Ann Hum Genet. 1977 May;40(4):385-401
pubmed: 879710
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590
Am J Hum Genet. 2007 Aug;81(2):383-7
pubmed: 17668387
Hum Mutat. 2005 Mar;25(3):323-4
pubmed: 15712224
Neurol Genet. 2018 Mar 20;4(2):e225
pubmed: 29564393
Am J Hum Genet. 2005 Jun;76(6):1081-6
pubmed: 15877282
J Clin Invest. 1994 Jun;93(6):2514-8
pubmed: 8200987
Mol Genet Genomic Med. 2019 Jul;7(7):e00698
pubmed: 31106992
Mol Genet Metab. 2016 May;118(1):28-34
pubmed: 26992325
PLoS One. 2017 May 2;12(5):e0176363
pubmed: 28463998
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
J Hum Genet. 2016 May;61(5):381-7
pubmed: 26818738
Neuropharmacology. 2016 Nov;110(Pt A):470-479
pubmed: 27544826
Annu Rev Pathol. 2010;5:297-348
pubmed: 20078222
Nat Genet. 1995 Oct;11(2):144-9
pubmed: 7550341
Trends Mol Med. 2011 Nov;17(11):641-9
pubmed: 21764377
Am J Hum Genet. 2012 Mar 9;90(3):518-23
pubmed: 22405087